|
Monday 8th December 2025 |
Text too small? |
Rua Bioscience is pleased to provide an update on the progress of its pro rata rights offer currently open to eligible shareholders.
To date the Company has received commitments for over $1.5 million from existing shareholders, with a total of $2 million on offer. This demonstrates strong support for Rua’s strategy and the objectives of the capital raise. These commitments reflect the confidence of shareholders in the Company’s commercial progress, operational execution, and long-term growth ambitions in the global medicinal cannabis sector.
The pro rata rights offer remains open until the end of day on Friday, 12 December 2025. Any shareholder that wishes to participate should do so before this date. Full details of the offer, including the timetable and instructions on how to take up rights, are set out in the Offer Document available at www.ruabio.com/capital-raise-november-2025.
Funds raised through the Rights Offer will be applied to working capital and marketing activities to support Rua’s growth opportunities, including the launch and commercialisation of new products across key international markets such as Germany, Australia, the United Kingdom, and Czechia.
ENDS
No comments yet
SPK-30 advanced with strategic review of Digital Services
FPH 2026 Notice of Annual Meeting and Voting Form
CNU - Q4 FY26 Connections Update
SPK - Spark announces appointment of Chief Operating Officer
SKC - Asset Monetisation Programme Update - The Grand Hotel
VCT - Full year results date & investor webcast details
ANZ - Air New Zealand 2026 Annual Results Webcast Details
SKC - Asset Monetisation Programme Update
July 17th Morning Report
MEL - Meridian Energy monthly operating report for June 2026